Laura Heacock¹, Joseph Weissbrot¹, Roy Raad¹, Naomi Campbell¹, Kent Friedman¹, Christian Geppert², and Hersh Chandarana^1
1Radiology, NYU Langone Medical Center, New York, NY, United States, ²Siemens Medical Solutions, New York, NY, United States

PET/CT is routinely performed in evaluation of disease burden in patients with Non Hodgkin Lymphoma (NHL). MRI with diffusion weighted imaging (DWI) has shown promise. In this study we compared the accuracy of morphologic MRI including DWI and PET/MR in detection of nodal disease with PET/CT as a reference. Our results suggest that PET/MR outperformed DWI for assessment of nodal disease and had sensitivity similar to PET/CT. Furthermore there was excellent correlation in SUVmax as measured with PET/MR and PET/CT. Thus PET/MR may be a viable option to PET/CT in evaluation of patients with lymphoma.

Omer Aras¹, Volkan Beylergil², Mark Hinton³, Olga Kubassova³, and Oguz Akin^4
1Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States, ²Radiology, Memorial Sloan Kettering Cancer, NY, United States, ³Image Analysis, London, United Kingdom, ⁴Radiology, Memorial Sloan Kettering Cancer, New York, NY, United States

In this preliminary data from 18F-FDG-PET/DCE-MRI in cervical cancer are reported. 18F-FDG PET and DCE-MRI tumor measures of tumor metabolism and vascularity were not correlated in this study indicating a complex interaction between tumor enhancement characteristics and tumor metabolism. information on the tumor.

Amy Melsaether¹, Akshat C. Pujara², Kristine Pysarenko², Roy A. Raad², Fabio Ponzo², Kent Friedman², Hersh Chandarana², Komal Jhaveri², Eric Sigmund², Sungheon Kim², and Linda Moy^2
1NYU, New York, New York, United States, ²NYU, New York, United States

In this prospective disease-specific study of 50 breast cancer patients, 18FDG-PET/MRI detected potentially treatment changing brain, liver and bone metastases not seen on PET/CT in 8 (16%) or patients and PET/CT occult in situ breast cancers in 5 (10%). Average 18FDG-PET/MRI radiation dose was 50% that of 18FDG-PET/CT.

Andrew B Rosenkrantz¹, Anne-Kristin Vahle¹, Christian Geppert², Christopher Glielmi², Fabio Ponzo¹, Kent P Friedman¹, Samir S Taneja³, Yu-Shin Ding¹, and Thomas Koesters^1
1Center for Advanced Imaging Innovation and Research, Department of Radiology, NYU Langone Medical Center, New York, NY, United States, ²Siemens Healthcare, Erlangen, Germany, ³Urologic Oncology, NYU Langone Medical Center, New York, New York, United States

This pilot study of 12 prostate cancer patients explores associations between metrics obtained from PET/MRI incorporating dynamic 18F-FDG PET imaging and biopsy findings. DCE-MRI and dynamic PET were performed simultaneously following sequential injections of gadolinium-chelate and FDG. Dynamic PET data was reconstructed in 30-second bins for the first 5 minutes, followed by 5-minute bins for the remainder of a 30-minute acquisition. Peak and 30-minute FDG activity were determined from FDG time-activity-curves and compared among benign and low- and high-grade tumors. The peak FDG activity showed the strongest association with biopsy results, supporting the value of dynamic PET imaging during PET/MRI.

Marcelo Queiroz¹, Christian Meerwein², Gerhard Huber², Martin Hüllner¹, Felix Kuhn¹, Spyros Kollias³, Gustav von Schulthess¹, and Patrick Veit-Haibach^1
1Medical Imaging, Zurich University Hospital, Zurich, Zurich, Switzerland, ²Otorhinolaryngology, Zurich University Hospital, Zurich, Switzerland,³Neuroradiology, Zurich University Hospital, Zurich, Switzerland

Our abstract compares the novel PET/MRI and the well established PET/CT in the follow-up of head and neck patients. PET/MRI emerges as a potential imaging modality that joins the functional ability of PET and the high-soft tissue contrast provided by MRI, but it might be shown the real advantages of this method.

Costanza Gianni'¹, Audrey Fan¹, Sindhuja Tirumalai Govindarajan¹, Marco Loggia¹, Nicole Zurcher Wimmer¹, Ciprian Catana¹, Jacob Hooker¹, Emanuele Tinelli², Celine Louapre¹, Thomas A Anderson³, R.P. Kinkel⁴, and Caterina Mainero^1
1Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, United States, ²Neurology and Psychiatry, Sapienza, University of Rome, Rome, Italy, ³Massachusetts General Hospital, Boston, MA, United States, ⁴Beth Israel Deaconess Medical Center, Boston, MA, United States

Inflammation through activation of macrophages and microglia is a prominent feature in multiple sclerosis. However, the relationship between activated microglia / macrophages and structural damage in the brain relies mainly on neuropathological studies. Here, we combined [11C]PBR28 imaging of activated microglia on a high resolution, simultaneous human MR-PET system with 7 Tesla in patients with secondary progressive multiple sclerosis. We observed diffuse microglia and macrophage activation across the cortex and WM, which topographically overlapped with visible lesions on 7 T T2* images in some regions.